Botanix Pharmaceuticals (BOT) News

ASXPrice sensitive

Neutral

22 Sept

director_dealing announcement

ASXPrice sensitive

Neutral

22 Sept

other announcement

Stockhead

Neutral

17 Sept

Dermatology focused Botanix Pharmaceuticals has embarked on a health kick in a bid to improve margins, cut costs and boost ... Read More The post Dr Boreham’s Crucible: Botanix Pharmaceuticals sweats it out as it embarks on health kick appeared first on Stockhead.

Kalkine

Neutral

15 Sept

Highlights Botanix Pharmaceuticals enters the September market backdrop with cash runway and margins becoming central to the broader discussion. Changing oil prices, elevated bond yields and shifting sector leadership are creating a more selective environment across Australian shares. The pharmaceutical developers cannabinoid-derived and dermatology programs make execution, funding resilience and commercial progress important areas to watch. The Australian share market is entering anothe...

Kalkine

Neutral

14 Sept

Highlights Botanix released its annual report after the initial full reporting period for its dermatology product launch. How commercial launch evidence frames a lower-priced healthcare company. Confirmed detail, rather than the surrounding commentary, is the standard this article applies when weighing what the news means for BOT. A fresh disclosure from Botanix Pharmaceuticals (ASX:BOT), a member of the All Ordinaries, states that botanix released its annual report after the initial full rep...

Kalkine

Neutral

14 Sept

Highlights Botanix released its annual report after the initial full reporting period for its dermatology product launch. How launch delivery and cash discipline frame the healthcare update. Confirmed detail, rather than the surrounding commentary, is the standard this article applies when weighing what the news means for BOT. A fresh disclosure from Botanix Pharmaceuticals (ASX:BOT), a member of the [All Ordinaries], states that botanix released its annual report after the initial full repor...

Kalkine

Neutral

14 Sept

Highlights Botanix reported a patent allowance covering the drug substance used by its commercial dermatology product. The update also falls within the Cannabis Stocks category, where broader sector conditions can shape how the disclosure is read. How intellectual property supports the company's cannabinoid-derived delivery platform history. Botanix Pharmaceuticals (ASX:BOT) has released a market update stating that Botanix reported a patent allowance covering the drug substance used by its c...

Kalkine

Neutral

14 Sept

Highlights Botanix reported progress toward a European patent covering its proprietary product applicator. The update also falls within the Cannabis Stocks category, where broader sector conditions can shape how the disclosure is read. How applicator protection supports the company's cannabinoid-derived delivery platform history. Botanix Pharmaceuticals (ASX:BOT) has released a market update stating that Botanix reported progress toward a European patent covering its proprietary product appli...

Kalkine

Neutral

14 Sept

Highlights Botanix released its annual report after the initial full reporting period for its dermatology product launch. The update also falls within the Cannabis Stocks category, where broader sector conditions can shape how the disclosure is read. How the annual report frames commercial delivery and the company's cannabinoid-derived platform history. Botanix Pharmaceuticals (ASX:BOT) has released a market update stating that Botanix released its annual report after the initial full reporti...

ASXPrice sensitive

Neutral

30 Aug

director_dealing announcement

ASXPrice sensitive

Neutral

30 Aug

other announcement

ASX

Neutral

25 Aug

other announcement

ASX

Neutral

25 Aug

other announcement

ASX

Neutral

13 Aug

other announcement

ASX

Neutral

13 Aug

other announcement

Kalkine

Neutral

12 Aug

Highlights Botanix Pharmaceuticals and Rhythm Biosciences are being assessed through operational delivery, strategic priorities and the quality of their underlying platforms. Dimerix and Amplia Therapeutics highlight how sector conditions can create different requirements across established and emerging business models. Capital discipline, customer relevance and consistent execution remain central as the four companies progress their current work programs. Australias market conversation is be...

Kalkine

Neutral

6 Aug

Highlights Botanix is in focus after it remained part of a selective healthcare and regulated-cannabis debate during reporting season, creating a current test of scalable earnings delivery. The Growth Stocks backdrop is shaped by revenue expansion, operating leverage and customer adoption as Australia's market trades near record levels. The central operating question is commercial execution in dermatology, with organic growth, margins, retention and reinvestment forming the evidence-based score...

Kalkine

Neutral

4 Aug

Highlights Botanix Pharmaceuticals's August reporting-season setup puts product rollout at the centre of the immediate market discussion. Australian penny stocks conditions keep Botanix Pharmaceuticals sensitive to demand, costs and working capital through the reporting cycle. For Botanix Pharmaceuticals, the test is whether working capital can support execution and financial flexibility through the next cycle. Australian shares enter the session with reporting season sharpening attention on ...

Kalkine

Neutral

3 Aug

Highlights Botanix Pharmaceuticals enters the reporting period with commercial launch execution central to the next company disclosure and the wider market debate. The Penny Stocks backdrop is testing liquidity, milestones and balance-sheet runway as rates, demand and capital discipline shape market interpretation. A comparison with Clinuvel Pharmaceuticals clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. Australia's listed market approa...

ASX

Neutral

2 Aug

other announcement

Kalkine

Neutral

28 July

Highlights Botanix sits inside a sharper regulated cannabis debate after thin sector news pushing attention back to balance sheets and product channels. Botanixs position in the earnings filter inside Cannabis Stocks rewards cleaner balance sheets, steadier revenue and credible execution. Cannabis Stocks around Botanix remain tied to local rates, offshore leads and company-specific operating evidence. The Australian share market moved into today's session with a cleaner risk tone, and Cann Gr...

ASX

Neutral

26 July

other announcement

ASX

Neutral

26 July

other announcement

Kalkine

Neutral

24 July

Highlights Botanix frames the penny stocks conversation as smaller names are being judged on funding discipline as the wider market turns cautious. ECS Botanics adds a second ASX reference point as traders compare cash runway, proof points and selective small-company trading. Commercial healthcare proof keeps the article focused on fresh market signals without drifting into directive language. Australia's share market is moving through a selective session, and ECS Botanics (ASX:ECS) gives pen...

Google News

Neutral

22 July

Botanix Pharmaceuticals (ASX: BOT): Healthcare Stock Retreats Amid Broader Sector Weakness  Kalkine

Kalkine

Neutral

9 July

Highlights Botanix Pharmaceuticals has attracted market attention after confirming inclusion in a widely followed benchmark index. The dermatology-focused biotechnology company continues progressing its lead prescription treatment through the United States regulatory process. A strengthened balance sheet has positioned the company for its next stage as commercial preparations gather pace. The Australian share market is continuing to reward healthcare compa...

Kalkine

Neutral

8 July

Highlights Botanix Pharmaceuticals is drawing attention as regulated medicinal access becomes a key measure for the Australian cannabis sector. Market focus has shifted towards commercial execution, regulatory clarity and disciplined capital management rather than sector-wide excitement. Little Green Pharma and Vitura Health provide useful comparisons as the medicinal cannabis landscape continues to evolve. Australia's share market is navigating another cautious tradin...

Kalkine

Neutral

6 July

Highlights Health microcap validation is shifting attention towards clinical evidence, commercial execution and reimbursement pathways. Botanix Pharmaceuticals (ASX:BOT), Orthocell (ASX:OCC) and AnteoTech (ASX:ADO) highlight different approaches to healthcare commercialisation. The market is rewarding business execution and operational credibility over broad sector enthusiasm. Australia's share market is entering the new financial year with a more selectiv...

Google News

Neutral

1 July

Botanix Pharmaceuticals (ASX:BOT): Why This ASX Biotech Stock Is Catching Investor Attention  Kalkine

Kalkine

Neutral

1 July

Highlights ASX cannabis stocks are being judged through earnings proof rather than headline momentum. Botanix Pharmaceuticals, ECS Botanics and Althea Group are shaping the medicinal cannabis discussion. Regulatory scrutiny, export credibility and manufacturing quality are becoming central market filters. ASX cannabis stocks are facing a sharper new financial year test as earnings proof, reg...

Kalkine

Neutral

30 June

Highlights ASX penny stocks are facing a sharper credibility test as biotech stories move from promise to validation. Botanix Pharmaceuticals, Radiopharm Theranostics and Dimerix help frame the microcap healthcare theme. Readers are watching funding discipline, clinical progress and commercial access as the next filters. ASX penny stocks face a sharper biotech proof test as microcap healthcare n...

Google News

Neutral

19 June

Botanix Pharmaceuticals (ASX:BOT): Healthcare Stock Keeps Traders Watching Beyond the Chart  Kalkine

Google News

Neutral

11 May

Botanix Pharmaceuticals (ASX:BOT) Shares Jump Today- What’s Driving the Momentum?  Kalkine

Google News

Neutral

16 Apr

Botanix Pharmaceuticals (ASX:BOT) lands Piramal API backup, targets 25% to 40% COGS cut  Stocks Down Under